Prespecified secondary analysis of EPIC-CAD (1040 patients with AF and stable coronary disease): edoxaban monotherapy had lower 12-month net adverse clinical events than edoxaban plus an antiplatelet in paroxysmal (4.6% vs 16.2%) and nonparoxysmal AF (9.3% vs 15.0%).
Secondary analysisn = 1,040
Yu et al. Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial